National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity seeking proposals to advance the understanding of the mechanisms of action, underlying biology, and clinical activity of talazoparib in prostate cancer.
NCCN views this collaboration with Pfizer as clear recognition of the advantages offered to investigators from all US institutions through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.
LOIs must be submitted by 5:00 pm ET on Monday, June 21, 2021. Please direct questions regarding this RFP to Nicole Kamienski at email@example.com with the subject line, “Pfizer Talazoparib 2021 Project.”